Joice Margareth de Almeida Rodolpho | Molecular Neuroscience | Best Researcher Award

Mrs. Joice Margareth de Almeida Rodolpho | Molecular Neuroscience | Best Researcher Award

Mrs. Joice Margareth de Almeida Rodolpho, Universidade Federal de São Carlos, Brazil.

Joice Margareth de Almeida Rodolpho is a dedicated Brazilian researcher with a strong foundation in biotechnology, parasitology, immunology, and molecular biology. She earned her Master’s and Ph.D. from the Federal University of São Carlos (UFSCar), where she explored the role of eosinophils as antigen-presenting cells in parasitic infections like Toxocara canis and Schistosoma mansoni. Her work is recognized for integrating experimental immunology with therapeutic innovations, such as the evaluation of natural plant extracts and nanomaterials for infection control. She further specialized in Flow Cytometry and Oncohematology, enhancing her analytical capabilities. With multiple awards and citations, her impactful contributions continue to strengthen Brazil’s standing in parasitological and immunological research.

Profile

Orcid

🎓 Early Academic Pursuits

Joice Margareth de Almeida Rodolpho began her academic journey in Brazil, developing a strong foundation in the life sciences. Her early interest in molecular biology and parasitology led her to pursue advanced studies at the esteemed Universidade Federal de São Carlos (UFSCar). She earned her Master’s degree in Biotechnology between 2009 and 2012, conducting significant research on Toxocara canis, particularly on the phenotypic characterization of eosinophils as antigen-presenting cells. This early work not only revealed her meticulous scientific inquiry but also laid the groundwork for her deeper exploration into immunology.

🧬 Professional Endeavors in Molecular and Evolutionary Genetics

Driven by a passion for understanding immune responses, Joice pursued a Ph.D. in Evolutionary Genetics and Molecular Biology at UFSCar from 2013 to 2017. Her doctoral research focused on the role of eosinophils as antigen-presenting cells both in vitro and ex vivo, offering vital insights into host-parasite interactions and immune regulation. Her work during this period was supported by a prestigious FAPESP scholarship, demonstrating her academic excellence and the relevance of her contributions. Under the mentorship of Professor Fernanda de Freitas Anibal, Joice refined her skills in experimental immunology and cellular biology.

🧪 Contributions and Research Focus in Parasitology and Immunopathology

Joice Rodolpho’s primary research interests lie at the intersection of parasitology, cellular immunology, and experimental pathology. Her studies explore how parasitic infections, such as those caused by Schistosoma mansoni and Toxocara canis, affect immune cell function, especially eosinophils. She has also contributed to investigations into natural plant extracts, like Mentha piperita L., assessing their therapeutic potential in modulating parasitic infections. Moreover, she extended her expertise to the field of nanomaterials, evaluating the cytotoxicity and cell death mechanisms induced by compounds like Ag₂WO₄, thus bridging classical parasitology with emerging biomedical technologies.

🏅 Accolades and Recognition in Scientific Circles

Throughout her career, Joice has received several recognitions that reflect the impact and originality of her research. In 2010, she was honored with a Menção Honrosa (Honorable Mention) for her work on Mentha piperita L. in treating Schistosoma mansoni, earning 2nd place in diagnostics and treatment. She continued to gain academic acclaim with awards at major conferences, including the VI Congresso da Sociedade Paulista de Parasitologia (2012) and the XXII B-MRS Meeting in 2024, highlighting her work on cytotoxic responses and innovative parasitological control methods. In 2024, her project on the parasitological and pathological evaluation of AW-HRL-C for schistosomiasis control was notably recognized by UNIFESP.

🧠 Impact and Influence in Experimental Immunology

Joice’s dedication to experimental immunology and cytometry has allowed her to mentor and influence upcoming researchers, especially in specialized fields such as flow cytometry. Her recent specialization in Immunology and Oncohematology by Flow Cytometry (2021–2022) at IPESSP further enriched her profile, showcasing her commitment to continuous learning and application of advanced technologies in immune profiling. Her ability to merge classical immunopathology with state-of-the-art cytometric tools reflects her versatility and forward-thinking scientific approach.

🌱 Legacy and Future Contributions in Biomedical Science

Poised to make lasting contributions, Joice Margareth de Almeida Rodolpho stands at the forefront of research into host-pathogen interactions, parasitic disease management, and immune cell function modulation. Her unique interdisciplinary approach—integrating molecular biology, natural product pharmacology, and immunological techniques—positions her as a valuable contributor to both academic research and potential therapeutic advancements. She is expected to lead innovative research in the treatment of neglected tropical diseases and immunological disorders, with implications for global health.

🔬 Research Field Relevance and Scientific Identity

As a scholar deeply embedded in the Brazilian scientific ecosystem, Joice’s identity is reflected in her multiple citation forms, indicating her widespread academic collaborations and international visibility. Her expertise bridges evolutionary genetics, biotechnology, cytometry, and immunoparasitology—making her a multifaceted researcher. Her contributions are cited under various names such as “RODOLPHO, JOICE M. A.” and “Joice Margareth de Almeida Rodolpho,” reflecting a robust presence in scholarly literature and ensuring her work continues to guide parasitological and immunological research for years to come.

Publication

  • Title: Biomarkers and Mental Disorders: A Relevance Analysis Using a Random Forest Algorithm
    Authors: Joice M. A. Rodolpho; Krissia F. Godoy; Bruna D. L. Fragelli; Jaqueline Bianchi; et al.
    Year: 2025

 

  • Title: Death Risk Score Model of Hospitalized COVID‐19 Patients: A Cohort Study
    Authors: Gustavo A. Cruz; Thais B. Boteon; Henrique Pott; Joice M. A. Rodolpho; et al.
    Year: 2025

 

  • Title: Synergistic Antifungal Effect and In Vivo Toxicity of a Monoterpene Isoespintanol Obtained from Oxandra xylopioides Diels
    Authors: Orfa I. C. Martínez; Alberto Angulo; Joice Rodolpho; Krissia F. Godoy; et al.
    Year: 2024

 

  • Title: Synergistic Antifungal Effect and In Vivo Toxicity of the Monoterpene Isoespintanol Obtained from Oxandra xylopioides Diels (Preprint)
    Authors: Orfa I. C. Martínez; Alberto Angulo; Joice M. A. Rodolpho; et al.
    Year: 2024

 

  • Title: Carbon Black CB-EDA Nanoparticles in Macrophages: Changes in the Oxidative Stress Pathway and in Apoptosis Signaling
    Authors: Joice M. A. Rodolpho; Krissia F. Godoy; Bruna D. L. Fragelli; et al.
    Year: 2023

 

  • Title: HGPRT and PNP: Recombinant Enzymes from Schistosoma mansoni and Their Role in Immunotherapy during Experimental Murine Schistosomiasis
    Authors: Bruna D. L. Fragelli; Ana C. Fattori; Joice M. A. Rodolpho; et al.
    Year: 2023

 

  • Title: Titanium Dioxide Nanoparticle (TiO2 NP) Induces Toxic Effects on LA-9 Mouse Fibroblast Cell Line
    Authors: Ana C. M. Fattori; Patricia Brassolatti; Joice M. A. Rodolpho; et al.
    Year: 2023

 

  • Title: Analysis of Cytotoxicity and Genotoxicity in a Short-Term Dependent Manner Induced by a New Titanium Dioxide Nanoparticle in Murine Fibroblast Cells
    Authors: Pedrino, M.; Brassolatti, P.; Joice M. A. Rodolpho; et al.
    Year: 2022

 

  • Title: Functionalized Titanium Nanoparticles Induce Oxidative Stress and Cell Death in Human Skin Cells
    Authors: Brassolatti, P.; Joice M. A. Rodolpho; Krissia F. Godoy; et al.
    Year: 2022

 

  • Title: Toxicological Effects of the Mixed Iron Oxide Nanoparticle (Fe₃O₄ NP) on Murine Fibroblasts LA-9
    Authors: Alves Feitosa, K.; Joice M. A. Rodolpho; et al.
    Year: 2022

 

🧾 Conclusion

Joice Rodolpho’s academic journey and scientific contributions reveal a researcher of high caliber, committed to advancing our understanding of host-pathogen dynamics and immune system function. Her work, grounded in rigorous experimentation and innovation, holds promise for developing novel therapies for neglected tropical diseases. With a forward-looking approach and interdisciplinary expertise, she stands out as a key contributor in biomedical science, poised to influence future discoveries in immunopathology and disease control.

Zhenhua Wu | Neurogenetics | Distinguished Scientist Award

Dr. Zhenhua Wu | Neurogenetics | Distinguished Scientist Award

Dr. Zhenhua Wu, Exegenesis Bio, Inc ,United States.

Zhenhua Wu is a distinguished biotech entrepreneur and scientific leader with over 20 years of experience across the research and development value chain. As the founder, President, and CEO of Exegenesis Bio Inc., he has pioneered accessible, innovative gene therapies for patients with unmet medical needs. His journey spans rigorous academic beginnings, executive leadership in multiple biotechnology companies, and a steadfast commitment to global health advancement. Known for assembling world-class talent and making strategic decisions, Wu has played a key role in shaping the future of gene therapy through both scientific and business excellence.

Profile

Orcid

 

🎓 Early Academic Pursuits

Zhenhua Wu’s journey into the world of biotechnology and gene therapy was shaped by a solid academic foundation rooted in scientific rigor and innovation. During his early academic pursuits, he demonstrated a deep curiosity for biological systems and therapeutic sciences. This intellectual appetite laid the groundwork for his future endeavors in translational medicine, where scientific discovery meets real-world application. His academic training not only honed his research skills but also instilled a lifelong commitment to innovation in the life sciences.

💼 Professional Endeavors

With more than two decades of hands-on experience in the research and development value chain, Zhenhua Wu has established himself as a seasoned leader in biotechnology. He has served in executive roles across a range of biotech companies of various sizes and strategic focuses. In each capacity, he brought visionary leadership, guiding teams to deliver impactful solutions in the biomedical space. His career has been a progressive climb from scientific inquiry to corporate strategy, integrating a robust understanding of science with sharp business acumen.

🧬 Contributions and Research Focus

As a pioneer in the field of gene therapy, Zhenhua Wu’s contributions are both profound and multifaceted. He is the founder and current President and CEO of Exegenesis Bio Inc., a multinational gene therapy company based in Philadelphia, PA. Under his leadership, the company has developed a pipeline of innovative, affordable gene therapies designed to address high unmet medical needs. His research focus lies in advancing next-generation gene therapies that are not only effective but also accessible, aiming to bridge the gap between scientific breakthroughs and patient care.

🏆 Accolades and Recognition

Zhenhua Wu’s impactful career has earned him recognition as a visionary entrepreneur and scientific innovator. Though his biography remains modest in tone, his work has resonated across the biotech sector, attracting significant investment and strategic partnerships. His ability to build and lead a cutting-edge biotech company from the ground up has marked him as a key influencer in gene therapy, with accolades stemming from both industry peers and investors who recognize the value and promise of his work.

🌍 Impact and Influence

Through Exegenesis Bio, Zhenhua Wu has catalyzed a new wave of therapeutic innovation with global reach. His influence extends beyond the lab and boardroom, impacting regulatory conversations, patient advocacy movements, and international biotech development. By forging cross-continental collaborations and assembling a top-tier team of experts, he has ensured that the company is positioned as a global leader in gene therapy solutions, redefining what is possible in patient care and drug development.

🧭 Legacy and Future Contributions

Looking ahead, Zhenhua Wu continues to chart a path focused on expanding access to gene therapy on a global scale. His legacy is being built not only through the therapies under development but also through the culture of scientific integrity, innovation, and purpose that he has instilled in his company. He remains dedicated to mentoring future leaders, cultivating partnerships that push boundaries, and shaping a future where life-altering treatments are within reach for all who need them.

🧠 Visionary Leadership in Gene Therapy

At the heart of Zhenhua Wu’s professional identity is his role as a visionary leader in the fast-evolving field of gene therapy. His ability to connect scientific breakthroughs with patient-focused strategies has transformed Exegenesis Bio into a beacon of hope for countless individuals suffering from genetic diseases. Through his relentless pursuit of innovation, ethical leadership, and commitment to excellence, he continues to redefine what leadership means in the life sciences industry.

Publication

  • Title: Tunneling Nanotubes and Gap Junctions–Their Role in Long-Range Intercellular Communication during Development, Health, and Disease Conditions
    Authors: Ariazi J, Benowitz A, De Biasi V, den Boer M, Cherqui S, Cui H, Douillet N, Eugenin EA, Favre D, Goodman S, et al.
    Year: 2017

 

  • Title: Quantitative assessment of Aβ peptide in brain, cerebrospinal fluid and plasma following oral administration of γ-secretase inhibitor MRK-560 in rats
    Authors: Wu G, Wu Z, Na S, Hershey JC
    Year: 2015

 

  • Title: Role of the MEOX2 homeobox gene in neurovascular dysfunction in Alzheimer disease
    Authors: Wu Z, Guo H, Chow N, Sallstrom J, Bell RD, Deane R, Brooks AI, Kanagala S, Rubio A, Sagare A, et al.
    Year: 2005

 

🔚 Conclusion

Zhenhua Wu’s career reflects the powerful intersection of science, leadership, and purpose. From building a visionary biotech enterprise to steering the development of transformative therapies, his contributions continue to resonate across the scientific community and healthcare industry. His legacy is not only defined by the innovations he leads today but also by the future he is helping shape—one where advanced gene therapies are more equitable, effective, and globally impactful. Through unwavering dedication and strategic foresight, he stands as a beacon of inspiration in the world of modern biotechnology.